Influenza Hemagglutinin (HA) Peptide: Precision Tag for Advanced Protein Workflow

Introduction and Principle: The Molecular Advantage of HA Tag Peptide

The Influenza Hemagglutinin (HA) Peptide (SKU: A6004) has redefined protein research by providing a compact, high-purity epitope tag for streamlined detection, purification, and protein-protein interaction studies. Derived from the influenza hemagglutinin epitope (sequence YPYDVPDYA), this synthetic nine-amino acid peptide functions as an ideal molecular biology peptide tag, enabling researchers to monitor and manipulate HA-tagged fusion proteins with precision. Its robust solubility profile (≥55.1 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, and ≥46.2 mg/mL in water) and >98% purity (HPLC and MS-validated) make it a trusted protein purification tag for complex experimental designs.

The HA tag peptide's mechanism hinges on its specific and high-affinity binding to anti-HA antibodies. This interaction allows selective detection and, crucially, competitive elution of HA fusion proteins during immunoprecipitation with Anti-HA antibody—an approach that stands at the forefront of modern proteomics and signal transduction research. The HA peptide’s utility is further underscored in translational studies, such as the recent investigation into E3 ligase-mediated suppression of colorectal cancer liver metastasis (Dong et al., 2025), where HA-tagged constructs were essential for dissecting protein interactions and post-translational modifications.

Step-by-Step Workflow: Enhanced Immunoprecipitation and Protein Purification with HA Tag

1. Construct Design and Expression

• HA Tag Integration: Incorporate the ha tag nucleotide sequence (coding for YPYDVPDYA) into the gene of interest. Codon optimization may be employed to maximize expression in the host cell system.
• Vector Choice: Select an expression vector with an in-frame ha tag dna sequence at the N- or C-terminus of the target protein.
• Expression: Transfect or transduce the construct into mammalian, yeast, or bacterial cells, ensuring robust fusion protein production.

2. Lysis and Pre-Clearing

• Cell Harvesting: Collect cells and lyse in a buffer compatible with downstream immunoprecipitation (e.g., Tris-buffered saline with protease inhibitors).
• Pre-clearing: Incubate lysate with non-specific IgG-bound beads to minimize background during immunoprecipitation.

3. Immunoprecipitation with Anti-HA Antibody

• Binding: Incubate cleared lysate with Anti-HA Magnetic Beads or conventional Anti-HA antibodies immobilized on agarose. The ha peptide tag enables highly specific capture of HA fusion proteins.
• Wash Steps: Perform rigorous washes to remove non-specific interactors.

4. Competitive Elution with HA Peptide

• Elution: Add synthetic Influenza Hemagglutinin (HA) Peptide directly to the bead-protein complex. The peptide competitively binds to the antibody, efficiently displacing the HA-tagged protein without harsh conditions.
• Optimization: Titrate the HA peptide concentration (typically 0.5–2 mg/mL) to maximize yield while preserving protein complexes or post-translational modifications.
• Collection: Recover the eluate for downstream analysis, such as Western blotting, mass spectrometry, or functional assays.

5. Analysis

• Validate protein identity and purity by SDS-PAGE and immunoblotting using anti-HA or target-specific antibodies.
• For interaction studies, probe co-immunoprecipitated partners or ubiquitination status, as demonstrated in the NEDD4L–PRMT5 axis investigation (Dong et al., 2025).

This workflow leverages the HA tag sequence’s compactness and immunogenicity, minimizing steric hindrance and maximizing compatibility with diverse detection systems.

Advanced Applications and Comparative Advantages

Protein-Protein Interaction and Ubiquitination Studies

The HA tag peptide has become indispensable for mapping protein networks and post-translational modifications. In the cited colorectal cancer metastasis study, HA-tagged PRMT5 enabled precise tracking of substrate ubiquitination by NEDD4L, unravelling a novel regulatory axis in oncogenic signaling. This mirrors the utility described in "Influenza Hemagglutinin (HA) Peptide as a versatile HA tag peptide for advanced protein-protein interaction and ubiquitination studies", which extends the mechanistic understanding of competitive binding and elution strategies in real-world disease models.

Precision Elution and Purity

Unlike traditional harsh elution methods (e.g., low pH or high salt), competitive binding to Anti-HA antibody by the synthetic peptide preserves protein conformation and multiprotein complexes. Quantitative comparisons show that >98% purity of the APExBIO HA tag peptide translates to minimal carryover and background—a benchmark echoed by "HA Peptide: Precision Tag for Accurate Protein Detection", which demonstrates high yield and reproducibility in complex lysates.

Workflow Flexibility

With its exceptional solubility (≥100.4 mg/mL in ethanol), the peptide can be directly integrated into a wide range of buffer systems without precipitation or loss of activity. This flexibility is particularly valuable for high-throughput and automated platforms, as highlighted in "Strategic Deployment of Influenza Hemagglutinin (HA) Peptide", which contrasts APExBIO’s product with legacy tags and details its adaptation to emerging clinical and translational research pipelines.

Troubleshooting and Optimization Tips

• Low Yield or Incomplete Elution: Ensure the peptide concentration is sufficient for competitive displacement. For stubborn complexes, increase peptide amount incrementally (up to 2 mg/mL) and extend incubation to 1 hour at 4°C.
• High Background or Non-Specific Binding: Incorporate additional pre-clearing and stringent wash steps. Validate antibody specificity and check for degradation of the antibody or peptide by proteases.
• Solubility Concerns: Use freshly prepared peptide solutions, leveraging its high solubility in ethanol or DMSO for stock preparations. Avoid repeated freeze-thaw cycles and long-term storage of diluted solutions; store the powder desiccated at -20°C for best stability.
• Loss of Protein-Protein Interactions: Optimize buffer composition to preserve native complexes. Use gentle, non-ionic detergents and minimize mechanical disruption.
• Validation of HA Tag Incorporation: Confirm correct insertion of ha tag nucleotide sequence by sequencing and validate expression by western blot with anti-HA antibody.

For additional real-world troubleshooting, "Practical Mastery: Influenza Hemagglutinin (HA) Peptide" benchmarks scenario-based solutions for assay variability, demonstrating how SKU A6004 consistently delivers sensitivity and reproducibility across diverse assay formats.

Future Outlook: Next-Generation HA Tag Applications

As molecular biology and translational research accelerate, the need for reliable, scalable, and adaptable peptide tags becomes paramount. The Influenza Hemagglutinin (HA) Peptide continues to anchor innovation in immunoprecipitation with Anti-HA antibody and next-generation protein-protein interaction studies. Ongoing work explores its use in proximity labeling, single-molecule tracking, and even clinical biomarker discovery workflows. Articles such as "Unlocking Mechanistic Precision: The Influenza Hemagglutinin (HA) Tag" extend these applications to exosome biology and clinical diagnostics, emphasizing the HA peptide's adaptability and translational value.

By integrating consistent performance, unmatched solubility, and competitive binding to Anti-HA antibody, APExBIO’s Influenza Hemagglutinin (HA) Peptide positions itself as the gold standard for protein research. Researchers can confidently deploy this hemagglutinin tag for diverse applications—ranging from routine detection to dissecting oncogenic signaling, as exemplified in the referenced NEDD4L–PRMT5 pathway study (Dong et al., 2025).

In summary: Whether optimizing immunoprecipitation, purifying labile multiprotein complexes, or spearheading mechanistic oncology research, the HA tag peptide from APExBIO delivers reproducibility, sensitivity, and workflow flexibility for the next era of molecular biology.